IbisVision, which is part of the Deepbridge Life Sciences EIS portfolio, has recently raised £4.5 million in growth funding as it seeks to open offices across the United States and sell its ground-breaking remote eye test platform into the world's richest healthcare markets. 

The money will be used to double its workforce and open an office in Fort Lauderdale, Florida. The company is poised to ramp up sales in the US, where it’s estimated there are around 110 million eye tests annually, after receiving Food and Drug Administration (FDA) listing in March. The company is also looking to tap into the eyecare market of the 448 million citizens across the European Union. IbisVision is already in discussions with a significant number of well-known eyecare brands to develop partnerships for its breakthrough platform. 

Reacting to the news CEO Mark Roger said: 

“The commitment of our investor base shows they believe strongly in our story — that eyecare will be at the vanguard of remote healthcare, and IbisVision has the technology to make this a reality. Our mission is simple – to make eyecare readily available for anyone on the planet and that distance and time will never be an impediment to getting to an eye appointment.” 

Ben Carter, Head of Life Sciences at Deepbridge Capital, said: 

“The continued progress of IbisVision shows the UK HealthTech industry can compete at the highest level. We are pleased to continue supporting this pioneering business whose technology has the potential to benefit patients globally.” 

Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).